Log Out

Global research to find creative and disruptive technologies

Global Database of Emerging Companies

The OneMedPlace Global Investment Platform aims to assist in bridging the funding gap for emerging growth companies. Qualified investors will soon be invited to log-in to participate in this network and contact companies directly.

An investor subscription to the platform will include access to business intelligence by research area – research reports, interviews, and posts curated by expert contributors – and deal-flow, with detailed multimedia-driven tear sheets and analyst summaries of companies in the space.

If you are an investor, you can pre-register by filling out this investor survey. Pre-registration to the Global Investment Platform will include a complimentary ticket to OneMedForumNY 2013, June26-27th at the Metropolitan Club in midtown NYC. Pre-registration also includes access to our deal-flow reports and subscription to our sector research reports.

*Your information will not be published or provided to any third party.

If you are a company executive and would like to learn more about our assets and reaching investors, contact Matt Margolis, Managing Editor, OneMedPlace at mmargolis@onemedplace.com or give us a call at 212.734.1008.

View companies by Research Sectors:

Aesthetics
Allergy
Audiology
Cardiology
Dental
Dermatology
Diabetes
Diagnostics
DrugDelivery

Gastroenterology
HIVAIDS
Imaging
Immunology
Infection Control
Infectious Disease
Neurology
Obesity
Oncology

Ophthalmology
Orthopedics
PainManagement
PatientMonitoring
Pediatrics
Psychiatry
Pulmonology
Renal
Rheumatology

Software Systems
Surgery
Telemedicine
Urology
Womens Health
WoundCare

searched: 1 - 30 of 22226 results Next >

Opexa Therapeutics

The Woodlands, TX, USA | Develops treatments for autoimmune diseases.

keywords: Regenerative medicine, immunotherapy, multiple sclerosis, secondary progressive multiple sclerosis, inflammatory disease, MS The Woodlands TX USA Neil Warma, President and Chief Executive Officer; Jaye Thompson, Ph.D., Senior-Vice President of Clinical Development and Regulatory Affairs; Don Healy Ph.D., Vice-President of Scientific Development and Manufacturing; Donna R. Rill, Senior Vice-President of Operations; John Ginzler

Amarantus BioScience

Sunnyvale, CA, USA | Biotechnology company that develops modifying treatments to address cell death.

keywords: Parkinsons Disease, PD, CNS, cell death, biotechnology, apoptosis, neurodegenerative diseases, cardiovascular diseases, cardiovascular, neurodegenerative, Parkinson\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'s disease

Biovista, Inc.

Charlottesville, United States | Repurposing drugs for unmet clinical needs.

keywords: ocular, opthalmology, diabetes, obesity, CNS, oncology Charlottesville VA United States Andreas Persidis Ph.D., CEO, Co-Founder; Aris Persidis Ph.D, President, Co-Founder; Graham Anthony, MBA

Wound Management Technologies Inc

Fort Worth, TX, USA | Provides collagen based wound care technology.

keywords: Wound care, regenerative medicine, woundcare Fort Worth TX USA Robert Lutz, CEO; Cathy Bradshaw, President of Wound Care Innovations, LLC Division; Barry E. Constantine, Project Consultant, Quality Manager

NanoViricides, Inc.

West Haven, CT, USA | Anti-viral drugs to fight HIV, influenza, and other infections

keywords: anti-viral drugs, HIVAIDS, dengue, influenza, herpes, adenovirus, keratitis, Immunology, DrugDelivery West Haven CT USA Eugene Seymour, MD, MPH

OncoSec Medical

San Diego, CA, USA | Developing novel, localized anti-cancer therapies to avert side-effects

keywords: Oncology, metastatic cancer, melanoma, metastasis, chemotherapy, immunotherapy, dermatology, DrugDelivery, San Diego CA USA Punit Dhillon, President and CEO; Caryn Peterson, Vice President

C3 International

Garden Grove, CA, USA | The first all natural medical marijuana pill.

keywords: Cannabinoid Therapeutic, Nutriceutical, Specialty Pharmaceutical, Pain Management Garden Grove CA USA Steele Smith, President and CEO.

Gerald Commissiong, , Amarantus BioScience Sunnyvale CA

Sunnyvale, CA, USA |

keywords: Gerald Commissiong

Martin Cleary, Chairman & CEO, Amarantus BioScience Sunnyvale CA

Sunnyvale, CA, USA |

keywords: Martin Cleary

Aris Persidis, President, Biovista, Inc. Charlottesville VA

Charlottesville, United States |

keywords: Aris Persidis

Graham Anthony, , Biovista, Inc. Charlottesville VA

Charlottesville, United States |

keywords: Graham Anthony

Deborah Hutchinson, President, Wound Management Technologies Inc Fort Worth TX

Fort Worth, TX, USA |

keywords: Deborah Hutchinson

Eugene Seymour, , NanoViricides, Inc. West Haven CT

West Haven, CT, USA |

keywords: Eugene Seymour

James Tong, Chief Financial Officer, Tianyin Pharmaceutical (TPI) Chengdu

Chengdu, China | Short Version:James Jiayuan Tong MD, PhD. is CFO, CBDO and Board Director of Tianyin Pharmaceuticals (NYSE Amex: TPI), headquartered at Chengdu, China. Prior to joining Tianyin in 2010, Dr. Tong was the Head of China Healthcare Investment Banking at ROTH Capital and before that a biotechnology analyst at Rodman & Renshaw. Prior to his Wall Street career, he was Principal Investigator at Marine Biological Laboratory at Woods Hole, MA and a Senior Research Fellow at University of California, Irvine. Dr. Tong was awarded Ph.D. in Neurobiology and Behavior from Cold Spring Harbor Laboratory / Stony Brook University Neuroscience program where he developed an innovative method to significantly extend life spans of animals based on his work on mitochondria, aging and learning disorders in Neurofibromatosis-1 (NF1) disease. He published three first-authored Nature articles and currently holds two patents. Dr. Tong received his medical degree from Peking University Health Science Center. Long version. Dr. James Jiayuan Tong Dr. Tong joined Tianyin as Chief Financial Officer and Chief Business & Development Officer, and a member of the Company's Board of Directors on April 1, 2010. Prior to his position at Tianyin, Dr. Tong was the Head of China Healthcare Investment Banking at ROTH Capital Partners, Newport Beach, CA. He initially joined ROTH as an equity research analyst, spearheading ROTH's effort in China healthcare universe, covering a series of U.S.-listed Chinese pharmaceutical, biotech, medical devices and drug retail businesses. Prior to that, Dr. Tong was a biotechnology analyst at Rodman & Renshaw, New York, covering biotech entities focusing on molecular diagnostics and cures for Alzheimer's disease, multiple sclerosis and cancer. Before his Wall Street career, Dr. Tong was Principal Investigator at Marine Biological Laboratory (MBL) sponsored by Grass Foundation at Woods Hole, MA and a Senior Research Fellow at University of California, Irvine (UCI). Dr. Tong was awarded Ph.D. in Neurobiology and Behavior from Cold Spring Harbor Laboratory / Stony Brook University Neuroscience program. He developed an innovative method to significantly extend life spans of animals based on his work on mitochondria, aging and learning disorders in Neurofibromatosis-1 (NF1) disease. He published three first-authored Nature articles and currently holds two patents. Dr. Tong received his medical degree from Peking University Health Science Center.

keywords: James Tong